These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 8963772)

  • 1. [Increased expression of decay-accelerating factor in patients with colonic neoplasms and the analysis of their feces].
    Mizuno M; Nakagawa M; Uesu A; Nasu J; Inaba T; Matsuoka Y; Kiso T; Fujiki S; Okada H; Fujita S
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):647-50. PubMed ID: 8963772
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunological tests: Decay-accelerating factor].
    Negoro T; Tobe T
    Nihon Rinsho; 2005 Jul; 63 Suppl 7():98-100. PubMed ID: 16111199
    [No Abstract]   [Full Text] [Related]  

  • 3. Difference in Ulex europaeus agglutinin I-binding activity of decay-accelerating factor detected in the stools of patients with colorectal cancer and ulcerative colitis.
    Okazaki H; Mizuno M; Nasu J; Makidono C; Hiraoka S; Yamamoto K; Okada H; Fujita T; Tsuji T; Shiratori Y
    J Lab Clin Med; 2004 Mar; 143(3):169-74. PubMed ID: 15007307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Decay-accelerating factor].
    Negoro T; Nakano Y
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():102-4. PubMed ID: 20942012
    [No Abstract]   [Full Text] [Related]  

  • 5. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM; Shuler C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stool decay-accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis.
    Kohno H; Mizuno M; Nasu J; Makidono C; Hiraoka S; Inaba T; Yamamoto K; Okada H; Fujita T; Shiratori Y
    J Gastroenterol Hepatol; 2005 Jan; 20(1):73-8. PubMed ID: 15610450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells.
    Andoh A; Shimada M; Araki Y; Fujiyama Y; Bamba T
    Cancer Immunol Immunother; 2002 Feb; 50(12):663-72. PubMed ID: 11862418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood.
    Pierson RN; Pino-Chavez G; Young VK; Kaspar-Konig W; White DJ; Wallwork J
    J Heart Lung Transplant; 1997 Feb; 16(2):231-9. PubMed ID: 9059935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Decay-accelerating factor (DAF; CD55)].
    Choi-Miura NH
    Nihon Rinsho; 1999 Nov; 57 Suppl():79-81. PubMed ID: 10635780
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis.
    Makidono C; Mizuno M; Nasu J; Hiraoka S; Okada H; Yamamoto K; Fujita T; Shiratori Y
    J Lab Clin Med; 2004 Mar; 143(3):152-8. PubMed ID: 15007304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
    Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
    Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the decay-accelerating factor CD55 as a peanut agglutinin-binding protein and its alteration in non-small cell lung cancers.
    Higuchi M; Endo Y; Suzuki H; Osuka F; Shio Y; Fujiu K; Kanno R; Oishi A; Fujita T; Gotoh M
    Clin Cancer Res; 2006 Nov; 12(21):6367-72. PubMed ID: 17085647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma.
    Chen S; Caragine T; Cheung NK; Tomlinson S
    Cancer Res; 2000 Jun; 60(11):3013-8. PubMed ID: 10850450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface expression of complement regulatory proteins, decay-accelerating factor (DAF) and CD59, on cultured human endothelial cells.
    Kunii H; Shichishima T; Saitoh Y; Noji H; Maruyama Y
    Fukushima J Med Sci; 1998 Dec; 44(2):69-81. PubMed ID: 10091379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
    Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
    Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New test identifies tumor markers in stool. Can colonic carcinomas now be detected earlier?].
    Klör HU
    MMW Fortschr Med; 2004 Sep; 146(35-36):13. PubMed ID: 15540530
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.
    Simpson KL; Jones A; Norman S; Holmes CH
    Am J Pathol; 1997 Nov; 151(5):1455-67. PubMed ID: 9358772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor.
    Kawada M; Mizuno M; Nasu J; Uesu T; Okazaki H; Okada H; Shimomura H; Yamamoto K; Tsuji T; Fujita T; Shiratori Y
    J Lab Clin Med; 2003 Nov; 142(5):306-12. PubMed ID: 14647034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.
    Durrant LG; Chapman MA; Buckley DJ; Spendlove I; Robins RA; Armitage NC
    Cancer Immunol Immunother; 2003 Oct; 52(10):638-42. PubMed ID: 12811528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.